Schering’s HCV combo gains indication
FDA approves new labeling for Schering-Plough's PegIntron (peginterferon alfa-2b) and Rebetol (ribavirin) combination therapy for treating chronic hepatitis C in patients with compensated liver disease, making it the first HCV combination approved in the U.S. that is not restricted to treatment-naïve patients. The label expansion, approved days after the announcement that Schering will merge with Merck, comes as the firm is moving ahead with Phase III trials of its direct antiviral for HCV, the protease inhibitor boceprevir
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.